Sera Prognostics Inc. Class A (SERA)
NASDAQ: SERAHealth CareMedical SpecialitiesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SERA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $71.98M
- EPS (TTM)
- -$0.67
- Dividend yield
- None
- 52-week range
- 1.56 – 3.85
- Day range
- 1.80 – 1.87
- Volume / Avg
- 94.60K / 27.84K
- Beta
- —
- Shares outstanding
- 38.80M
52-week range
SERA stock today
On Nov 20, SERA ended the session at $1.81, shedding $0.08 (4.23%), versus the S&P 500's 3.70% decline. Volume was 3.4x the average at 94.60K shares, a sign of unusually heavy trading. Shares are 53.0% below their 52-week high of $3.85, set on Jan 8, 2026 and 16.0% above the 52-week low of $1.56, near the bottom of the past year's range.
SERA is down 38.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 44.0%. Sera Prognostics has posted a net loss over the last twelve months (EPS of -$0.67), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Sera Prognostics
Company profileSera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction.
- Sector
- Health Care
- Industry
- Medical Specialities
- CEO
- Ms. Zhenya Lindgardt M.B.A.
- Headquarters
- Salt Lake City, UT
- Employees
- 71
- IPO year
- 2021
- Website
- sera.com
Financial highlights
Full financialsIn fiscal 2025, Sera Prognostics generated $81,000 in revenue, up 5.2% from fiscal 2024. Sera Prognostics reported a net loss of $31.9 million, compared with a loss of $32.9 million a year earlier. Gross margin was -102.5% (down from -6.5%) and operating margin -45066.7%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $81.00K | $77.00K | $306.00K | $268.00K | $82.00K |
| Growth | +5.19% | -74.84% | +14.18% | +226.83% | +228.00% |
| Net income | $-31.93M | $-32.90M | $-36.24M | $-44.19M | $-35.01M |
| EPS (diluted) | $-0.67 | $-0.99 | $-1.16 | $-1.43 | $-2.33 |
Analyst forecast
ForecastConsensus (4 analysts)
none
Avg. price target
$5.50+203.87%
- Strong buy 0
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.16 vs $-0.14
- Surprise
- -14.29%
SERA news
All SERA news- Sera: 3 Key Takeaways for Long-Term InvestorsNasdaq
- Sera Prognostics (SERA) Q3 2026 Earnings Call TranscriptNasdaq
- Sera Prognostics Reports Third Quarter 2026 Financial ResultsNasdaq
- SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF THIRD QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON NOVEMBER 4, 2026PR Newswire
Sera Prognostics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BDSXBiodesix Inc. | 7.56 | -8.92% | $83.83M | vs SERA |
| XGNExagen Inc. | 3.61 | -5.00% | $92.10M | vs SERA |
| KEQUKewaunee Scientific Corporation | 33.55 | -2.75% | $97.14M | vs SERA |
| MDXHMDxHealth SA | 0.1074 | -8.52% | $10.25M | vs SERA |
| AMSAmerican Shared Hospital Services | 1.00 | -4.76% | $6.67M | vs SERA |
| BNRBurning Rock Biotech Limited ADR | 13.24 | -0.60% | $139.63M | vs SERA |
| ACONAclarion Inc. | 1.22 | -13.92% | $3.52M | vs SERA |
| ADVBAdvanced Biomed Inc. | 1.65 | -5.71% | $2.73M | vs SERA |
Indexes, lists and sector
Sera Prognostics stock FAQ
What is Sera Prognostics's stock price today?
SERA last traded at $1.81 as of Nov 20, 4:00 PM EST, down 4.23% on the day. Prices are delayed at least 15 minutes.
Who is Sera Prognostics's CEO?
Ms. Zhenya Lindgardt M.B.A. is the chief executive officer of Sera Prognostics Inc. Class A, which has about 71 employees.
What is the SERA 52-week high?
The 52-week high for SERA is $3.85 and the 52-week low is $1.56. The stock is currently 53.0% below its high.